ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Landos Biopharma Inc

Landos Biopharma Inc (LABP)

22.93
0.00
(0.00%)
Closed May 29 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
22.93
Bid
22.40
Ask
24.08
Volume
-
0.00 Day's Range 0.00
2.50 52 Week Range 22.94
Market Cap
Previous Close
22.93
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
26,920
Shares Outstanding
3,116,729
Dividend Yield
-
PE Ratio
-3.26
Earnings Per Share (EPS)
-7.04
Revenue
-
Net Profit
-21.94M

About Landos Biopharma Inc

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and me... Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Landos Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LABP. The last closing price for Landos Biopharma was $22.93. Over the last year, Landos Biopharma shares have traded in a share price range of $ 2.50 to $ 22.94.

Landos Biopharma currently has 3,116,729 shares outstanding. The market capitalization of Landos Biopharma is $71.47 million. Landos Biopharma has a price to earnings ratio (PE ratio) of -3.26.

LABP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.572.5491949910622.3622.9422.364289822.87593691CS
40.472.0926090828122.4622.9421.911213122.53036685CS
1216.38250.0763358786.5522.945.572692019.99493235CS
2618.28393.118279574.6522.943.211723215.78146179CS
5219.94666.8896321072.9922.942.51498810.55549004CS
156-87.07-79.1545454545110161.72.11112657618.12288184CS
260-107.07-82.3615384615130169.892.11113401834.16088543CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
BNAIBrand Engagement Network Inc
$ 2.6062
(105.21%)
108.22M
ONCOOnconetix Inc
$ 0.2949
(79.93%)
137.82M
ASTSAST SpaceMobile Inc
$ 9.0199
(69.23%)
109.9M
KTRAKintara Therapeutics Inc
$ 0.272
(44.76%)
81.59M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
AWINAERWINS Technologies Inc
$ 5.555
(-39.22%)
2.01M
HLTHCue Health Inc
$ 0.0553
(-38.96%)
72.11M
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
PLTNUPlutoniam Acquisition Corporation
$ 5.83
(-34.57%)
965
GWAVGreenwave Technology Solutions Inc
$ 0.0494
(-37.15%)
676.15M
LUCYInnovative Eyewear Inc
$ 0.9393
(129.10%)
576.2M
FFIEFaraday Future Intelligent Electric Inc
$ 0.4379
(-62.57%)
417.92M
RSLSReShape Lifesciences Inc
$ 0.2847
(37.01%)
212.55M
AALAmerican Airlines Group Inc
$ 11.62
(-13.54%)
159.16M

LABP Discussion

View Posts
pitacorp pitacorp 1 year ago
i did the same the other day, at 61 average in after market..will buy again on the next correction, which will be very soon..
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP...HERE WE GO...60S
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
BOOM...60C BID ...GOING TO A DOLLA
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
lmao...gapping...another lesson taught
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
Boom breaking 50s. Next dollar runner
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP READY TO RUMBLE AGAIN
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP nice close and ready to pop next week
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP one more try here on the 46c break
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP heres a 46c bid....key break
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP lets see that all important 46c break here
๐Ÿ‘๏ธ0
gail gail 1 year ago
hopped back out for aโ€ฆ

โ€ฆ

small profit before the dump but im watching it.

this is a bouncy one for sure.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
lmao...38c to 58c keep watching the magic
๐Ÿ‘๏ธ0
ANTI-BAGHOLDER ANTI-BAGHOLDER 1 year ago
Doh! LMAO
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
grabbed a few 41s on that sell off...holding the 50 day...only one target and that would be the 100 day...chart is not bullish
๐Ÿ‘๏ธ0
gail gail 1 year ago
a/h trading looking good. Iโ€ฆ.

โ€ฆ

guess i will be on this run by myself, the board got quiet.
๐Ÿ‘๏ธ0
gail gail 1 year ago
here we goooo!!!
๐Ÿ‘๏ธ0
gail gail 1 year ago
congrats. i got in on the dip.
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
SOLD ON THAT PUSH
๐Ÿ‘๏ธ0
pitacorp pitacorp 1 year ago
yeah, but it is breaking the other way now....
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
WHAMO....30 MILLION FLOAT
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
MONSTER
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP HERES THE 46 BREAK...MONSTER
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP 43c ask stack on a good 60 min...
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP 42s getting smashed
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 year ago
LABP getting jiggy...46c break sends it
๐Ÿ‘๏ธ0
RAND RAND 1 year ago
Another 30% today, betting news gonna drop, lotta volume
๐Ÿ‘๏ธ0
RAND RAND 1 year ago
$LABP in +23.5% Uptrend, growing for three consecutive days on December 13, 2022. View odds for this and other indicators: https://t.co/2GkAz2CU82 #LandosBiopharma pic.twitter.com/XIfQQ40Ry4— Tickeron (@Tickeron) December 14, 2022
๐Ÿ‘๏ธ0
Hungry_Ghost Hungry_Ghost 2 years ago
ER being released Aug 11 after market closeโ€ฆ
๐Ÿ‘๏ธ0
Hungry_Ghost Hungry_Ghost 2 years ago
Thanksโ€ฆ.
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
August 03 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clinical trial of NX-13, a novel, oral, NLRX1 agonist in development for the treatment of ulcerative colitis (UC) as a once-daily oral therapy. The data showed that NX-13 was well tolerated following evaluation of multiple doses over four weeks compared with a placebo.
Based on these results, the Company plans to initiate a Phase 2 clinical trial to evaluate the safety, efficacy, and optimal dosing of NX-13 in UC patients.

โ€œWe are pleased to announce the successful completion of our Phase 1b trial of NX-13, which marks an important milestone for Landos,โ€ said Gregory Oakes, President and CEO of Landos. โ€œNX-13 showed a favorable safety and tolerability profile in UC patients across a range of doses. While the study was shorter in duration than standard induction trials and not powered for efficacy, there was an indication of promising signals of clinical improvement as soon as two weeks in patientsโ€™ symptoms and four weeks by endoscopy in exploratory endpoints. This early signal, as well as the data from a long-term toxicology study, support the potential of NX-13 as an important new treatment for UC. Landos is eager to advance the learnings from this Phase 1b trial through further analysis of its clinical, pharmacokinetic, and pharmacodynamic data and an appropriately designed proof of concept trial. To this end, Landos plans to advance this product candidate into a Phase 2 clinical trial.โ€

The Phase 1b study was a randomized, double-blind, placebo-controlled study to evaluate safety and pharmacokinetics of NX-13 at multiple dose levels, which was orally administered once-daily over four weeks. 38 adult patients with active UC with a total Mayo score between four and ten were enrolled in the study. Dose arms of 250mg immediate release (IR), 500mg IR, and 500mg modified release (MR) were tested, with each arm containing 11 participants. Five participants received a placebo.

Across the four cohorts, no serious adverse events (SAEs) were reported, consistent with earlier studies in healthy volunteers and preclinical models.

โ€œThe continued development of NX-13 is one of several important initiatives underway at Landos,โ€ continued Mr. Oakes. โ€œSince joining the Company in June, I have been working closely with the Board of Directors to review the business and finalize the development of a focused plan to advance the pipeline and optimize successful outcomes for our three clinical-stage programs. There is positive momentum underway at Landos, and we are optimistic about the potential for NX-13 for patients suffering from UC. We look forward to providing a comprehensive update on our clinical development plans later this year.โ€

About NX-13
NX-13 is a novel, gut-restricted, orally active, small molecule therapeutic candidate for the treatment of UC. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 is designed to increase oxidative phosphorylation in immune cells, reduce differentiation of effector CD4-positive T cells, and decrease production of inflammatory cytokines in the gastrointestinal tract.

About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. We believe we were the first to identify and target LANCL2, NLRX1 and PLXDC2, which are immunometabolic pathways or targets. We have identified seven novel immunometabolic pathways or targets based on predictions of immunometabolic function using a proprietary advanced artificial intelligence-based integrated computational and experimental precision medicine platform. Our near-term focus is on our clinical-stage programs including omilancor for the treatment of UC, NX-13 for the treatment of UC, and LABP-104 for the potential treatment of systemic lupus erythematosus and rheumatoid arthritis.

For more information, please visit www.landosbiopharma.com.

Cautionary Note on Forward-Looking Statements
๐Ÿ‘๏ธ0
Hungry_Ghost Hungry_Ghost 2 years ago
O/S. 40 million
Float 11.25 million
Insiders 10 million
Institutions 26 million
Short shares 115,000

These are the facts as I know them. I am not pumping .
News on trial progress due mid year. Good news and the price goes up. Bad trial news will hurt financially due to low daily volume.
They need to reign in spending as 70 million doesnโ€™t go far nowadays.

GL, May all your trades work outโ€ฆ.
๐Ÿ‘๏ธ0
Harbor6460 Harbor6460 2 years ago
How about the float or As or OS. Good pump
๐Ÿ‘๏ธ0
Hungry_Ghost Hungry_Ghost 2 years ago
Great expansive pipeline, 70 million million in the bank, well connected experienced management and all for 70 measly Pennieโ€™s a share.

LANDOSBIOPHARMA.COM for more infoโ€ฆ
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock